The consciousness coefficient in patients with axon diffusion. Disorders of multiple cranial nerves
Conditions
Interventions
Intervention 1: Patients in the intervention group will receive two doses of Modafinil 100 mg (manufactured by Subhan Pharmaceutical Company) daily. Intervention 2: Patients in the control group will
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients aged 18 to 75 years Patients who did not have a serious life-threatening illness before the brain injury diagnosed with diffuse axonal damage based on neurosurgery expert diagnosis and imaging findings. patients who are able to receive medication by oral or nasogastric tube.
Exclusion criteria
Exclusion criteria: Lack of informed consent by the patient's first-degree relatives severe intracranial hematoma and Progressing and/or extensive brain contusion with an indication for surgery participation in another clinical trial within the last month spinal cord injury penetrating head injury chronic steroid use history of cerebrovascular injury, brain tumor or previous traumatic brain injury midline change of more than 5 mm and/or bilateral or extensive brain contusion and/or subarachnoid hemorrhage identified on CT scan or MRI failure Kidney pregnancy history of allergy to modafinil drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GCS score and GOS score. Timepoint: Three and six months after head trauma. Method of measurement: Assessment of cognitive level. | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE score. Timepoint: 0,1,3 and 7 days and discharge day. Method of measurement: MMSE scores are considered as normal cognitive function with a score of 25-30, mild impairment with a score of 20-24, moderate impairment with a score of 10-19, and severe impairment with a score of 0-9. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Fateme Saghafi
Yazd University of Medical Sciences
Outcome results
None listed